Radar · Oncology in France
Best Oncology Companies in France
The 169 best Oncology companies in France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Inventiva Pharma.
By Riya SenguptaFinancials
169companies tracked
$2.4Bdisclosed funding
0unicorns
90have raised
France's oncology sector, 169 companies deep and carrying $2.4B in disclosed funding, is one of the more serious concentrations of cancer-drug capital in Europe. Inventiva Pharma alone has pulled in $433M, which tells you something about the appetite here. Ab Science follows at $83M, Step Pharma at $52M. No unicorns yet, but the funding stack is real and the global market these companies are chasing is substantial: oncology is forecast to grow at an 11.5% CAGR through 2034, with precision medicine and rising cancer incidence doing most of the pulling. Cost-containment policies in France add pressure on pricing, but they haven't slowed deal flow from Bpifrance, Kurma Partners, and the EIC Fund.
So what's actually moving the science? As shown in 2019 research, patient support structures matter alongside clinical advances, and France's ecosystem reflects that, with hot coverage themes spanning cancer biomarkers, angiogenesis inhibitors, and counseling oncology. I'd argue the biomarker angle is the one to watch. The 169 companies we track here are ranked by disclosed equity funding and recent momentum, so if you're mapping where serious capital has actually landed in French oncology, this is the list to start with.
Sources & further reading
- Pharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s contin
- Oncology Market Is Encouraged to Reach USD 646.33 Billion by 2032
- Oncology Market Value to More Than Double, Reaching USD 748.17 Billion
FLIAR INTELLIGENCE · ONCOLOGY × FRANCE
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
272kcombined LinkedIn audience
37%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Oncology companies in France
| # | Company | Disclosed funding | Last round | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Inventiva Pharma Provider of therapeutic solutions for fibrosis, lysosomal storage disorders and oncology 72Growth top 20%Product top 24%Funding top 26%Market top 40% All 10 signals ▾Growthtop 20% Producttop 24% Fundingtop 26% Markettop 40% Talenttop 41% Innovationtop 43% Fin. healthtop 46% Moattop 48% Techbottom 48% Globalbottom 46% Growth: Revenue +44% YoY · Web rank 10,000,000 → 5,000,000 YoY Product: 2 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 72/100 | $433M | 20 mo ago | 117 | Frederic Cren CEO & Co-Founder | — | — | 1 award |
| 2 | Cellectis Developer of cancer immunotherapies based on gene-edited CAR T-cells 64Patents top 20%Funding top 25%Product top 29%Innovation top 30% All 11 signals ▾Patentstop 20% Fundingtop 25% Producttop 29% Innovationtop 30% Newstop 33% Markettop 38% Moattop 41% Globaltop 45% Growthtop 48% Talentbottom 49% Techbottom 46% Patents: 1,579 patents matched (strict assignee match) · 326 filings since 2022 vs 610 in 2017-21 Funding: Raised $267M across 3 rounds · 3 rounds over 12 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $267M | 25 mo ago | 236 | Andre Choulika Chief Executive Officer | 6 signals IPO · Announcements · Earnings | 1,579 patents Patents concentrated in chemistry & materials | — |
| 3 | Imcheck Therapeutics Developer of immunotherapeutic antibodies for the treatment of multiple diseases 55Patents top 21%Funding top 24%Moat top 26%Innovation top 27% All 9 signals ▾Patentstop 21% Fundingtop 24% Moattop 26% Innovationtop 27% Markettop 49% Talentbottom 49% Globalbottom 45% Techbottom 30% Newsbottom 27% Patents: 104 patents matched (strict assignee match) · 75 filings since 2022 vs 29 in 2017-21 Funding: Raised $185M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $185M | 21 mo ago | 48 | Pierre D'epenoux Chief Executive Officer | — | 104 patents Patents concentrated in chemistry & materials | — |
| 4 | Enterome Developer of immunomodulatory drugs targeting cancer and immune diseases | $130M | 71 mo ago | 70 | — | — | 188 patents Microbiome-derived antigenic peptides for cancer immunotherapy and B‑cell malignancy treatment | — |
| 5 | Quantum Surgical Provider of surgical robotics for minimally invasive surgeries | $98M | 26 mo ago | 98 | Fernand Badano Co-Founder | — | 224 patents Image‑guided needle placement and robotic navigation for minimally invasive procedures | — |
| 6 | Mnemo Therapeutics Developer of cell therapy platforms for tumors and blood cancer | $91M | 60 mo ago | 56 | Alain Maiore Co-Founder & ex-CEO | — | 58 patents Neoantigen peptide vaccines and SUV39H1‑targeted epigenetic immunotherapies for cancer. | — |
| 7 | AB Science Developer of tyrosine kinase inhibitors for multiple disease indications 42Funding top 20%Patents top 21%Innovation top 28%Moat top 28% All 9 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 28% Moattop 28% Newstop 33% Growthtop 45% Techbottom 41% Globalbottom 38% Marketbottom 21% Funding: Raised $83.2M across 9 rounds · 9 rounds over 9 yrs (1.0/yr) Patents: 461 patents matched (strict assignee match) · 78 filings since 2022 vs 86 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $83M | 1 mo ago | 3 | — | 3 signals ▲200% Earnings · Funding · Capital raise | 461 patents Small-molecule kinase and tubulin inhibitors for oncology and rare disease therapies | — |
| 8 | PDC*line Pharma Developer of therapeutic vaccines for the treatment of cancer | $65M | 54 mo ago | 34 | Joel Plumas Co-Founder & Cso | — | — | — |
| 9 | TheraVectys Developer of vaccines to treat infectious diseases and cancer caused by HTLV-1 infection | $62M | 64 mo ago | 19 | Ye Tian CEO | — | 176 patents Lentiviral vector platforms for viral antigen vaccines and gene‑therapy immunotherapies | — |
| 10 | Advanced Accelerator Applications Novartis company, developing molecular nuclear medicine theranostics | $56M | 134 mo ago | 1,038 | — | — | 215 patents Formulating stable, concentrated radiopharmaceutical complexes for diagnostic and therapeutic use. | — |
| 11 | Carthera Devices focused on the treatment of brain tumors | $55M | 30 mo ago | 20 | — | — | 96 patents Implantable acoustic lens devices for brain imaging and therapy | — |
| 12 | Step Pharma Developer of targeted oncology therapies inhibiting CTPS1 for cancer treatment 35Patents top 20%Innovation top 26%Moat top 29%Funding top 31% All 11 signals ▾Patentstop 20% Innovationtop 26% Moattop 29% Fundingtop 31% Newstop 43% Growthtop 45% Techbottom 46% Globalbottom 44% Talentbottom 41% Fin. healthbottom 26% Marketbottom 20% Patents: 109 patents matched (strict assignee match) · 73 filings since 2022 vs 36 in 2017-21 Innovation: 109 patents (top 27% of patent-holders) · 73 filings since 2022 vs 36 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $52M | 3 mo ago | 12 | Andy Parker President & CEO | — | 109 patents Small-molecule CTPS1/CTPS2 inhibitors for treating proliferative and hematologic cancers | 2 awards |
| 13 | Domain Therapeutics Developer of GPCR‑targeted immuno‑oncology and inflammation drug candidates | $51M | 49 mo ago | 107 | Sean MacDonald CEO | — | 132 patents Therapeutic antibodies for CCR8 and small‑molecule modulators of EP4 and PAR‑2. | — |
| 14 | Egle Therapeutics Provider of T cells based therapeutics for oncology and autoimmune diseases 45Funding top 34%Talent top 38%Moat top 39%Patents top 40% All 7 signals ▾Fundingtop 34% Talenttop 38% Moattop 39% Patentstop 40% Innovationbottom 49% Marketbottom 44% Globalbottom 43% Funding: Raised $46.6M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $47M | 15 mo ago | 28 | Eliane Piaggio Co-Founder | — | 11 patents Engineered cytokine therapeutics and biomarkers for cancer immunotherapy | — |
| 15 | Innate Pharma Developer of antibody based therapeutics to treat cancer 76Fin. health top 17%Patents top 21%Funding top 28%Talent top 28% All 11 signals ▾Fin. healthtop 17% Patentstop 21% Fundingtop 28% Talenttop 28% Innovationtop 32% Markettop 34% Moattop 40% Globaltop 48% Techbottom 49% Growthbottom 47% Newsbottom 47% Fin. health: Revenue ~$62.3M (FY2016) · Net margin 23.3% Patents: 1,175 patents matched (strict assignee match) · 266 filings since 2022 vs 455 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $43M | 13 mo ago | 191 | Marc Bonneville Co-Founder | 4 signals ▼60% Earnings · Announcements | 1,175 patents Engineered antibody and cell therapies targeting immune checkpoints and cancer antigens | — |
| 16 | MaaT Pharma Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases | $42M | 59 mo ago | 71 | Herve Affagard Founder and Chief Executive Officer | — | 171 patents Patents concentrated in health & consumer products | 1 internship |
| 17 | Genticel Developer of immunotherapies to treat infectious diseases and cervical cancer using CyaA vector technology | $41M | 157 mo ago | 32 | — | — | 50 patents CyaA-based chimeric protein vaccine vectors for therapeutic and prophylactic immune responses | — |
| 18 | Mablink Provider of Antibody-Drug-Conjugates (ADC's) technology for cancer treatment | $35M | 44 mo ago | 29 | Charles Dumontet Co-Founder | — | — | — |
| 19 | Waiv Developer of AI-powered diagnostic tools for precision oncology and pathology 48Funding top 26%AI top 35%Talent top 38%Global bottom 48% All 6 signals ▾Fundingtop 26% AItop 35% Talenttop 38% Globalbottom 48% Techbottom 45% Marketbottom 31% Funding: Raised $33.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: ai-powered, machine learning rank vs industry peers · Fliar Intelligence Index 48/100 | $33M | 3 mo ago | — | Lionel Guillou Co-Founder & CTO | — | — | — |
| 20 | Adcytherix Developer of therapeutics for the treatment of cancer 40Growth top 15%News top 22%Funding top 31%Moat top 42% All 8 signals ▾Growthtop 15% Newstop 22% Fundingtop 31% Moattop 42% Talentbottom 49% Globalbottom 39% Marketbottom 28% Techbottom 20% Growth: Fresh capital in last 24 mo News: 6 BI events in 12 mo (of 8 tracked, 3 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $32M | 8 mo ago | — | Carsten Dehning Co-Founder | 6 signals Funding · Capital raise · Fundraising | — | 1 award |
| 21 | HalioDx Developer of diagnostic product for colon cancer | $31M | 89 mo ago | 240 | — | — | — | — |
| 22 | Hybrigenics R&D for new targets & therapies against proliferative diseases | $28M | 201 mo ago | 200 | — | — | 216 patents Antibody therapeutics and vitamin D analog small‑molecule immuno‑oncology agents | — |
| 23 | Advesya Developer of therapies for the treatment of cancer and autoimmune diseases | $26M | 53 mo ago | — | Ksenija Pavletic Chief Executive Officer | — | 8 patents IL-1RAP-targeted antibody‑drug conjugates and CAR‑T cell immunotherapies for cancer | — |
| 24 | Brenus Pharma Developer of immunotherapy for the treatment of cancer | $25M | 21 mo ago | 12 | Jacques Gardette CEO | — | — | — |
| 25 | Qubit Pharmaceuticals Developer of drugs for the treatment of cancer and inflammatory diseases | $25M | 45 mo ago | 50 | Jay Ponder Co-Founder | — | 15 patents Quantum algorithms for molecular simulation and optimized quantum circuit design for chemistry | 2 partnerships |
| 26 | GamaMabs Developer of engineered monoclonal antibodies for the treatment of ovarian cancer | $22M | 126 mo ago | 7 | — | — | — | — |
| 27 | SquareMind Developer of robotic medical equipment for skin cancer detection 50AI top 15%Patents top 28%Innovation top 32%Moat top 32% All 9 signals ▾AItop 15% Patentstop 28% Innovationtop 32% Moattop 32% Fundingtop 38% Talentbottom 49% Globalbottom 43% Techbottom 41% Marketbottom 26% AI: Holds AI/ML patents (G06N-family CPC) Patents: 57 patents matched (strict assignee match) · 48 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $21M | 1 mo ago | 10 | Ali Khachlouf Co-Founder & CEO | — | 57 patents Robotic arm guidance systems and AI-driven medical imaging marker generation | — |
| 28 | Tridek One Provider of therapeutics for immuno-inflammatory diseases | $19M | 45 mo ago | 5 | — | — | — | — |
| 29 | Iktos Artificial Intelligence for new drug design | $16M | 39 mo ago | 55 | Nicolas Do Huu Co-Founder & CTO | — | — | — |
| 30 | NH TherAguix Developer of nanoparticle-based theranostic for the treatment of cancer | $16M | 86 mo ago | 18 | — | — | 94 patents Nanoparticle-based drug delivery and radiopharmaceutical imaging/therapy | — |
| 31 | VitaDX Early diagnostics for bladder cancer 35Funding top 35%Tech top 44%Moat top 48%Talent bottom 49% All 6 signals ▾Fundingtop 35% Techtop 44% Moattop 48% Talentbottom 49% Globalbottom 38% Marketbottom 36% Funding: Raised $14.4M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Tech: 27 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 35/100 | $14M | 9 mo ago | 29 | Allan Rodriguez CEO | — | — | — |
| 32 | OSE Immunotherapeutics Developer of immunotherapies for immuno-oncology and autoimmune diseases | $14M | 26 mo ago | 61 | — | 14 signals ▲180% Leadership · Announcements · Lawsuit | 601 patents Targeted lipid nanoparticle delivery of immunomodulatory peptides and antibodies for cancer immunotherapy | — |
| 33 | Rarecells Developer of noninvasive tests for earlier cancer diagnoses | $13M | 54 mo ago | 22 | — | — | 20 patents Rare cell isolation, filtration, and liquid biopsy biomarker analysis for cancer and blood disorder diagnostics | 1 partnership · 1 award |
| 34 | Flash Therapeutics Provider of gene-based therapeutics for multiple disorders | $12M | 59 mo ago | 49 | — | — | 37 patents Apelin-based lymphedema therapy and viral RNA/genome‑editing delivery platforms | — |
| 35 | Nanobiotix Developer of nanotherapeutics designed to enhance cancer treatment via radioenhancement | $11M | 30 mo ago | 102 | — | 14 signals ▲600% Earnings · Funding · Contracts | 478 patents Patents concentrated in health & consumer products | 1 partnership |
| 36 | DAMAE Medical Developer of imaging diagnostic device for skin cancer | $10M | 52 mo ago | 32 | Anais Barut Co-Founder & CEO | — | 65 patents Advanced optical microscopy systems for ex vivo and in vivo tissue imaging and ROI analysis | 1 job opening |
| 37 | EverImmune Developer of live biotherapeutic products as oral adjuvants to cancer immunotherapies | $9M | 33 mo ago | 7 | Romain Dalliere Co-Founder | — | 18 patents Microbiome-based diagnostics and biomarkers for predicting cancer immunotherapy response | — |
| 38 | Oncovita Developer of virus-derived vaccine technology to treat cancer | $9M | 30 mo ago | 2 | Frederic Tangy Co-Founder | — | — | 1 partnership |
| 39 | Netris pharma Developer of therapeutic solutions to treat cancer | $8M | 30 mo ago | 14 | — | — | 120 patents Patents concentrated in chemistry & materials | — |
| 40 | Apmonia Therapeutics Developer of peptide-based therapeutics for cancer | $8M | 23 mo ago | 11 | Stephane Dedieu Co-Founder | — | — | 1 award |
| 41 | Hemerion Developer of therapeutic solutions for the treatment of cancer | $7M | 12 mo ago | 14 | Maximilien Vermandel Co-Founder & CEO | — | — | 1 partnership |
| 42 | Hephaitos Pharma Developer of immunotherapies for the treatment of cancer | $7M | 25 mo ago | — | Alexey Novikov Co-Founder | — | — | — |
| 43 | HEPTA Medical Developer of minimally invasive non-surgical treatment for cancer | $6M | 21 mo ago | 7 | Thomas Bancel CEO | — | — | — |
| 44 | ErVimmune Developer of immunotherapies for the treatment of cancer 16News top 36%Moat top 38%Funding top 40%Patents top 44% All 9 signals ▾Newstop 36% Moattop 38% Fundingtop 40% Patentstop 44% Talentbottom 49% Innovationbottom 48% Globalbottom 36% Marketbottom 25% Techbottom 23% News: 3 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents rank vs industry peers · Fliar Intelligence Index 16/100 | $5M | 4 mo ago | — | Stephane Depil Founder | 3 signals Funding | 9 patents HERV-based cancer epitope discovery and AML diagnostic/therapeutic biomarkers | 1 job opening |
| 45 | Oncodesign Provider of preclinical assessment services for anticancer therapies 55Patents top 34%Product top 36%Moat top 40%Market top 42% All 10 signals ▾Patentstop 34% Producttop 36% Moattop 40% Markettop 42% Fundingtop 43% Innovationtop 44% Growthtop 45% Globaltop 49% Techbottom 47% Newsbottom 27% Patents: 157 patents matched (strict assignee match) · 20 filings since 2022 vs 77 in 2017-21 Product: 2 distinct product lines · Company stage: Acquired rank vs industry peers · Fliar Intelligence Index 55/100 | $5M | 3 mo ago | 238 | — | — | 157 patents Macrocyclic small‑molecule kinase inhibitors for RIP2 and LRRK2 therapeutic targets | — |
| 46 | EverImmune Developer of biotherapeutics for the treatment of cancer | $4M | 33 mo ago | — | Romain Daillere Co-Founder | — | 18 patents Microbiome diagnostic biomarkers for predicting cancer immunotherapy response | — |
| 47 | Odimma Provider of immunotherapy for the cancer treatment | $3M | 37 mo ago | 8 | Jean-Marc Limacher Co-Founder | — | — | — |
| 48 | Allogenica Biotechnology company specializing in the development of allogeneic CAR-T therapies for cancer treatment | $3M | 15 mo ago | — | Inna Menkova Co-Founder & CEO | — | — | — |
| 49 | BiPER Therapeutics Developer of small molecule drugs for cancer treatment | $855K | 6 mo ago | 7 | Rachid Benhida Co-Founder | — | 10 patents Small-molecule sulfonamide‑thiazole anticancer agents for targeted cancer therapy | — |
| 50 | TheraPPI Biotech company developing protein interaction solutions for cancer and related diseases | $113K | 14 mo ago | — | Stephane Giraud Co-Founder | — | — | — |
Top 12 Oncology companies in France
#1
Public · Paris, Ile de France · founded 2001 · 3 employees$83.2Mraised▾
Public · Paris, Ile de France · founded 2001 · 3 employees
Developer of tyrosine kinase inhibitors for multiple disease indications. The company's lead candidate drugs are masitinib, a highly selective tyrosine kinase inhibitor, and AB8939, a new generation microtubule destabilizer for oncology, neurodegenerative and inflammatory indications.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 20%Patents
top 21%Innovation
top 28%Moat
top 28%News
top 33%Growth
top 45%Funding: Raised $83.2M across 9 rounds · 9 rounds over 9 yrs (1.0/yr) · Last round Post IPO (May 2026)
Patents: 461 patents matched (strict assignee match) · 78 filings since 2022 vs 86 in 2017-21 · Latest publication 2025
Innovation: 461 patents (top 5% of patent-holders) · 78 filings since 2022 vs 86 in 2017-21
Funding rounds
- May 2026Post IPO$3M
- Oct 2025Post IPO$3.3M
- Jul 2025Post IPO$2.3M
- May 2025Post IPO$2M
Tech stack
Contact Form 7Core-JsGoogle AnalyticsGoogle Font ApiGsapIsotope
#2
Series C · Saint-Genis-Pouilly, Auvergne-Rhone-Alpes · founded 2014 · 12 employees$51.7Mraised▾
Series C · Saint-Genis-Pouilly, Auvergne-Rhone-Alpes · founded 2014 · 12 employees
Developer of targeted oncology therapies inhibiting CTPS1 for cancer treatment. The company focuses on creating selective, orally bioavailable drugs for blood cancers and solid tumors. Their lead asset is in clinical development for lymphoma, ovarian cancer, and essential thrombocythaemia. Future development may include treatment regimens for solid tumours.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Patents
top 20%Innovation
top 26%Moat
top 29%Funding
top 31%News
top 43%Growth
top 45%Patents: 109 patents matched (strict assignee match) · 73 filings since 2022 vs 36 in 2017-21 · Latest publication 2026
Innovation: 109 patents (top 27% of patent-holders) · 73 filings since 2022 vs 36 in 2017-21
Moat: Editorial + unicorn rating 7/10 · IP moat: 109 patents · Soonicorn
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Feb 2026Grant (prize money)$3M
- Oct 2025Series C$44M
- Mar 2021Series B$41.6M
- Nov 2017Series A$10.1M
Founders & team
Investors
Hadean Ventures, Sunstone, Kurma Partners, Pontifax, Bpifrance, Inserm Transfert Initiative
#3
Seed · Paris, Ile de France · founded 2019 · 10 employees$20.6Mraised▾
Seed · Paris, Ile de France · founded 2019 · 10 employees
Developer of robotic medical equipment for skin cancer detection. It offers autonomous robots equipped with third-dimension construction software that capture data by full-body mapping to detect skin cancer. It allow physicians to track the growth of moles on the body using off-the-shelf robots.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
AI
top 15%Patents
top 28%Innovation
top 32%Moat
top 32%Funding
top 38%Talent
bottom 49%AI: Holds AI/ML patents (G06N-family CPC)
Patents: 57 patents matched (strict assignee match) · 48 filings since 2022 vs 9 in 2017-21 · Latest publication 2026
Innovation: 57 patents (top 44% of patent-holders) · 48 filings since 2022 vs 9 in 2017-21 · Deep-tech classification: Tech Hardware
Funding rounds
- Apr 2026Seed$18M
- Jul 2022Grant (prize money)$2.6M
- 2022Grant (prize money)—
- Seed—
Founders & team
Investors
EIC Fund, Europa, Sonder Capital, Bpifrance, Adamed Technology, Teampact Ventures
Tech stack
Amazon Web ServicesHstsLenisNode.JsNuxt.JsOpen Graph
#4
Series C · France · founded 2026$33Mraised▾
Series C · France · founded 2026
Developer of AI-powered diagnostic tools for precision oncology and pathology. It provides clinically validated AI tests to streamline diagnostic workflows and ignite biomarker discovery. The company leverages machine learning, foundation models, pathology, and oncology expertise. It utilizes diverse datasets to reinforce model performance and accelerate clinical translation.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 26%AI
top 35%Talent
top 38%Global
bottom 48%Tech
bottom 45%Market
bottom 31%Funding: Raised $33.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series C (Mar 2026)
AI: Product described with: ai-powered, machine learning
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Mar 2026Series C$33M
Founders & team
Investors
OTB Ventures, AIC, Serena, Karista, SISTAFUND
Tech stack
Apple Icloud MailCloudflareCookiebotGoogle AnalyticsGoogle Font ApiGoogle Hosted Libraries
#5
Public · Daix, Bourgogne Franche Comte · founded 2012 · 117 employees$433.2Mraised▾
Public · Daix, Bourgogne Franche Comte · founded 2012 · 117 employees
Provider of therapeutic solutions for fibrosis, lysosomal storage disorders and oncology. Its offers a lead product candidate lanifibranor for the treatment of patients with non-alcoholic steatohepatitis, or NASH. It also offers odiparcil for the treatment of patients with mucopolysaccharidoses which is a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Growth
top 20%Product
top 24%Funding
top 26%Market
top 40%Talent
top 41%Innovation
top 43%Growth: Revenue +44% YoY · Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Product: 2 distinct product lines · Company stage: Public
Funding: Raised $433M across 3 rounds · 3 rounds over 11 yrs (0.3/yr) · Last round Post IPO (Oct 2024)
Audience (LinkedIn): 9k LinkedIn followers — 3.4% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Oct 2024Post IPO$379.6M
- Sep 2019Post IPO$9.1M
- Apr 2018Post IPO$44.5M
- Sep 2016Grant (prize money)—
Founders & team
Investors
Eureka, BVF Partners, Novo Holdings, Sofinnova Partners, New Enterprise Associates, Schonfeld
Tech stack
Apache Http ServerBootstrapCloudflareCloudflare Bot ManagementCookieyesFont Awesome
#6
Series A · Marseille, Provence Alpes Cote d Azur · founded 2023$32.3Mraised▾
Series A · Marseille, Provence Alpes Cote d Azur · founded 2023
Developer of therapeutics for the treatment of cancer. It offers antibody drug conjugates to treat pathologies in high medical need, notably cancer.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Growth
top 15%News
top 22%Funding
top 31%Moat
top 42%Talent
bottom 49%Global
bottom 39%Growth: Fresh capital in last 24 mo
News: 6 BI events in 12 mo (of 8 tracked, 3 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: Funding, Capital raise, Fundraising
Funding: Raised $32.3M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Oct 2025)
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series A$122M
- Jun 2024Seed$32.3M
Founders & team
Investors
Pontifax, Pureos Bioventures, RA Capital Management, Dawn Biopharma, Bpifrance, Kurma Partners
#7
Acquired · Dijon, Bourgogne Franche Comte · founded 1995 · 238 employees$4.7Mraised▾
Acquired · Dijon, Bourgogne Franche Comte · founded 1995 · 238 employees
Oncodesign is an oncology preclinical CRO company that provides an assessment of anti-cancer therapies. It has three platforms, PREDICT - conventional in vitro and in vivo pharmacology, Chi-Mice - in vivo chimeric humanized models, and PharmImage - multimodal, non-invasive pharmaco-imaging. It uses Nanocyclix technology, for discovery activity that gives access to potent and selective macrocyclic kinase inhibitors.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Patents
top 34%Product
top 36%Moat
top 40%Market
top 42%Funding
top 43%Innovation
top 44%Patents: 157 patents matched (strict assignee match) · 20 filings since 2022 vs 77 in 2017-21 · Latest publication 2025
Product: 2 distinct product lines · Company stage: Acquired
Moat: Editorial + unicorn rating 3/10 · IP moat: 157 patents · 10 curated direct competitors tracked
Funding rounds
- Mar 2026Grant (prize money)$6.9M
- May 2008Series A$4.7M
Investors
Banque de Vizille, Avenir Entreprises, The Michael J. Fox Foundation, Credit Mutuel Equity, Elyan Partners
Tech stack
Adobe Audience ManagerAosApache Http ServerAutoptimizeBackbone.JsBrowser-Update.Org
#8
Public · Marseille, Provence Alpes Cote d Azur · founded 1999 · 191 employees$43.5Mraised▾
Public · Marseille, Provence Alpes Cote d Azur · founded 1999 · 191 employees
Developer of antibody-based therapeutics to treat cancer. The company's portfolio include lacutamab, developed in an advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab in non-small cell lung cancer, as well as ANKET multi-specific NK cell engagers to address multiple tumor types.
Fliar Intelligence Index™ 76how this company ranks against its industry peers
Fin. health
top 17%Patents
top 21%Funding
top 28%Talent
top 28%Innovation
top 32%Market
top 34%Fin. health: Revenue ~$62.3M (FY2016) · Net margin 23.3% · Revenue 1.4x total funding
Patents: 1,175 patents matched (strict assignee match) · 266 filings since 2022 vs 455 in 2017-21 · Latest publication 2026
Funding: Raised $43.5M across 9 rounds · 9 rounds over 27 yrs (0.3/yr) · Last round Post IPO (Apr 2025)
Audience (LinkedIn): 32k LinkedIn followers — 11.7% of this cohort's audience
Funding rounds
- Apr 2025Post IPO$17.1M
- Jun 2018Grant (prize money)$306.7K
- Jan 2017Post IPO$15M
- Jun 2014Post IPO$68.1M
Founders & team
Investors
QVT Family Office, Redmile Group, Orbimed, Sofinnova Partners, Alta Partners, Ardian
Tech stack
Apple Icloud MailBootstrapCloudflareDrupalFancyboxFont Awesome
#9
Acquired · Marseille, Provence Alpes Cote d Azur · founded 2015 · 48 employees$185.1Mraised▾
Acquired · Marseille, Provence Alpes Cote d Azur · founded 2015 · 48 employees
Developer of immunotherapeutic antibodies for the treatment of multiple diseases. It offers a new generation of proprietary immunomodulatory antibodies acting on both adaptive and innate immunity (notably gamma-delta T-cells). It offers therapeutics for cancer, infectious disease, and autoimmune disease.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Patents
top 21%Funding
top 24%Moat
top 26%Innovation
top 27%Market
top 49%Talent
bottom 49%Patents: 104 patents matched (strict assignee match) · 75 filings since 2022 vs 29 in 2017-21 · Latest publication 2026
Funding: Raised $185M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) · Last round Grant (prize money) (Aug 2024)
Moat: Editorial + unicorn rating 8/10 · IP moat: 104 patents · Soonicorn
Audience (LinkedIn): 12k LinkedIn followers — 4.3% of this cohort's audience
Funding rounds
- Aug 2024Grant (prize money)$22.4M
- Jun 2022Series C$103M
- Sep 2020Series B$7.1M
- Dec 2019Series B$53.2M
Founders & team
Investors
Pureos Bioventures, Government of France, Bpifrance, Boehringer Ingelheim Venture Fund, Kurma Partners, Idinvest Partners
Tech stack
Typo3 CmsPhpBootstrapAnimate.CssApache Http ServerCloudflare
#10
Series A · Lyon, Auvergne Rhone Alpes · founded 2019$4.8Mraised▾
Series A · Lyon, Auvergne Rhone Alpes · founded 2019
Developer of immunotherapies for the treatment of cancer. The company combines cancer vaccines and T-cell therapies to create treatments based on the identification of new families of tumor antigens.
Fliar Intelligence Index™ 16how this company ranks against its industry peers
News
top 36%Moat
top 38%Funding
top 40%Patents
top 44%Talent
bottom 49%Innovation
bottom 48%News: 3 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding
Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents
Funding: Raised $4.8M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series A (Jan 2026)
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Bioinformatics Engineers, Data Scientists – Immuno-Oncology
Funding rounds
- Jan 2026Series A$19.8M
- Jun 2023Grant (prize money)$15.4M
- Jan 2023Seed$4.8M
Founders & team
Investors
EIC Fund, Seventure Partners, Bpifrance, SPRIM Global Investments
Tech stack
Apple Icloud MailComplianzDiviFont AwesomeGoogle Font ApiJquery
#11
Series B · Evry Courcouronnes, Ile de France · founded 2015 · 29 employees$14.4Mraised▾
Series B · Evry Courcouronnes, Ile de France · founded 2015 · 29 employees
VitaDx develops early diagnostics for bladder cancer. The company uses a proprietary protocol that uses digital analysis to analyze urine and detect selective fluorescence around bladder cancer cells. VitaDx claims that this fluorescence detects cells with greater accuracy and sensitivity than traditional staining protocols, even in early stages of the disease.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 35%Tech
top 44%Moat
top 48%Talent
bottom 49%Global
bottom 38%Market
bottom 36%Funding: Raised $14.4M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) · Last round Series B (Aug 2025)
Tech: 27 technologies across 4/8 capability areas · Cloud: Cloudflare · Devops: Nginx
Moat: Editorial + unicorn rating 5/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Aug 2025Series B$1.7M
- Oct 2024Series B$7.1M
- Apr 2024Series A$7M
- Sep 2020Series A$1.2M
Founders & team
Investors
GO CAPITAL, Odyssee Venture, BNP Paribas, CIC, Banque Populaire, Caisse D Epargne
Tech stack
BootstrapCloudflareCloudflare Bot ManagementCloudflare Browser InsightsCookieyesCore-Js
#12
Series A · Paris, Ile de France · founded 2020 · 28 employees$46.6Mraised▾
Series A · Paris, Ile de France · founded 2020 · 28 employees
Provider of T cells-based therapeutics for oncology and autoimmune disease. The company offers computational-based IL-2 modified variants and translational-based therapeutic Treg targets to restore the immune response.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 34%Talent
top 38%Moat
top 39%Patents
top 40%Innovation
bottom 49%Market
bottom 44%Funding: Raised $46.6M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Grant (prize money) (Mar 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · IP moat: 11 patents · Soonicorn
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- Mar 2025Grant (prize money)$10.1M
- Oct 2021Series A$46.6M
Founders & team
Investors
Bioqube Ventures, Takeda, Fund+, Life Sciences Partners, Bpifrance, T1D Fund
Funding & investor landscape
$2.4Btotal disclosed funding
87companies funded
260disclosed rounds
2rounds last 90 days
Most active investors
Notable founders
Andy Parker
President & CEO · Step Pharma
Ali Khachlouf
Co-Founder & CEO · SquareMind
Lionel Guillou
Co-Founder & CTO · Waiv
Meriem Sefta
Co-Founder & CEO · Waiv
Frederic Cren
CEO & Co-Founder · Inventiva Pharma
Carsten Dehning
Co-Founder · Adcytherix
Marc Bonneville
Co-Founder · Innate Pharma
Jean-Jacques Fournie
Co-Founder · Innate Pharma
Pierre D'epenoux
Chief Executive Officer · Imcheck Therapeutics
Stephane Depil
Founder · ErVimmune
Allan Rodriguez
CEO · VitaDX
Eliane Piaggio
Co-Founder · Egle Therapeutics
Prism market signals · France · country-scoped Prism corpus, 2,001,202 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · France
How research on Oncology & Cancer Therapeutics is moving in France
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,281 France-affiliated papers.
research sentiment over time
201120182026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 51% → 64% across 2011–2026.
top research entities
- Inserm449
- Centre National de la Recherche Scientifique358
- Institut Gustave Roussy102
- Assistance Publique – Hôpitaux de Paris102
- Institute of Cancer Research91
leading researchers
Guido Kroemer · Stéphanie Corgnac · Jean‐Philippe Guégan · Sheng, Ling-Shuang · Shen, Rong · Yan, Zi-Xun · Wang, Chao · Zheng, Xin
▲
Breakthroughs446 · 35%
▲ 23%→36% share
▲1.6× share momentum1 median citations89% since 2021mostly methods-led
Tumor microenvironment breakthroughs are surging — French oncology papers rose from 14 to 174, driving field-share from 23% to 36%.
rising sub-themes (early→recent)
- Tumor microenvironment14→174
- Immune system8→130
- Cancer research16→128
- Immunotherapy3→114
- Cancer immunotherapy2→62
Newly emergingInternal medicine 0→20 · T cell 0→19 · Breast cancer 0→18
Landmark Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression · 3,923 cites
◆
Advancements551 · 43%
43%→43% share
▲1.0× share momentum2 median citations85% since 2021mostly empirical
Immunotherapy advancement research intensified sharply — French institutional papers scaled from 14 to 178 within Advancements segment.
rising sub-themes (early→recent)
- Tumor microenvironment26→212
- Immune system26→194
- Immunotherapy14→178
- Cancer research23→153
- Cancer immunotherapy9→73
Newly emergingInternal medicine 0→25 · Transcriptome 0→24 · T cell 0→22
Landmark Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota · 3,336 cites
▼
Concerns137 · 11%
▼ 16%→10% share
▼0.6× share momentum4 median citations81% since 2021mostly reviews
Concern-flagged research is shrinking — field-share dropped 16% to 10% despite Tumor microenvironment concern papers rising 9 to 53.
rising sub-themes (early→recent)
- Immune system7→51
- Tumor microenvironment9→53
- Immunotherapy8→50
- Cancer research3→30
- Cancer immunotherapy6→19
Newly emergingClinical trial 0→9 · Oncolytic virus 0→8 · Breast cancer 0→8
Landmark The clinical role of the TME in solid cancer · 736 cites
RESEARCH HOTSPOTS · France
Where oncology is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Paris362 · +0.51
Marseille83 · +0.57
Lyon66 · +0.42
Toulouse34 · +0.54
Grenoble20 · +0.53
Strasbourg13 · +0.76
PATENT SIGNAL · France
Who's filing oncology patents in France
France oncology patent filing is cooling — 203 filings from 69 assignees (2016–2025), led by Cellectis, INST NAT Sante RECH MED, Centre NAT RECH Scient; annual filings 17→16.
203 filings69 assigneespeak 27/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Cellectis124
- INST NAT Sante RECH MED61
- Centre NAT RECH Scient26
- UNIV Claude Bernard LYON19
- UNIV Sorbonne18
- Hopitaux Paris Assist Publique17
- Roussy INST Gustave15
- Centre LEON Berard13
Common questions
How many Oncology companies are there in France?
Radar tracks 169 indexable Oncology companies headquartered in France that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in France?
The Oncology companies in France on this list have raised a combined $2.4B in disclosed equity funding across 87 funded companies.
Which is the highest-funded Oncology company in France?
Inventiva Pharma is the highest-funded Oncology company in France, with $433.2M in disclosed equity funding.
How many Oncology companies in France are funded?
87 of the 169 Oncology companies in France on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in France?
None of the Oncology companies in France on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in France Oncology companies?
The most active investors in France Oncology companies on this list include Bpifrance, Europa, EIC Fund, Kurma Partners, Auriga Partners.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.